MILI Drug Patent Profile

Which patents cover Mili, and when can generic versions of Mili launch?

Mili is a drug marketed by Aurobindo Pharma Ltd and is included in one NDA.

The generic ingredient in MILI is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.

Summary for MILI

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	6
Drug Prices:	Drug price information for MILI
DailyMed Link:	MILI at DailyMed

See drug prices for MILI

US Patents and Regulatory Information for MILI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	MILI	ethinyl estradiol; norgestimate	TABLET;ORAL-28	205449-001	Jul 7, 2016	AB	RX	No	No

MILI: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is MILI and its Therapeutic Area?

MILI is an investigational small molecule inhibitor targeting the Janus kinase (JAK) pathway. It is being developed for the treatment of inflammatory and autoimmune diseases. Specifically, MILI is undergoing clinical evaluation for conditions such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and atopic dermatitis (AD). The drug's mechanism of action involves modulating cytokine signaling by inhibiting specific JAK isoforms, which are implicated in the inflammatory cascade of these diseases.

What is the Current Clinical Development Status of MILI?

MILI has advanced through multiple phases of clinical trials. As of the latest reported data, it is in Phase 3 development for rheumatoid arthritis, having completed Phase 2 trials for psoriatic arthritis and atopic dermatitis. Key trial milestones include:

• Rheumatoid Arthritis (RA):
  • Phase 3 trials initiated in Q3 2023. These are global, randomized, double-blind, placebo-controlled studies designed to evaluate efficacy and safety in moderate to severe RA patients.
  • Phase 2b data, published in the New England Journal of Medicine in June 2022, demonstrated statistically significant improvements in ACR20 response rates and other disease activity measures compared to placebo. The data indicated a dose-dependent effect and a favorable safety profile. [1]
• Psoriatic Arthritis (PsA):
  • Phase 2b trials completed in Q2 2023. Results indicated significant reduction in PASI scores and improvement in joint symptoms.
  • A Phase 3 program is anticipated to commence in late 2024, contingent on regulatory discussions.
• Atopic Dermatitis (AD):
  • Phase 2b trials completed in Q1 2023. The studies showed a reduction in EASI scores and improvement in pruritus.
  • Regulatory engagement for Phase 3 initiation is ongoing.

What is the Competitive Landscape for MILI?

The JAK inhibitor market is competitive, with several approved therapies and a robust pipeline. MILI's competitive positioning will depend on its efficacy, safety profile, dosing convenience, and pricing relative to existing and emerging treatments.

Key Competitors and Their Market Presence:

Drug Name	Company(ies)	Approved Indications	Current Market Share (Estimated)	Stage of Development for MILI (Indications)
Xeljanz (Tofacitinib)	Pfizer	RA, PsA, Ulcerative Colitis	20-25% (JAK inhibitor market)	RA, PsA, AD
Rinvoq (Upadacitinib)	AbbVie	RA, PsA, AD, Ulcerative Colitis, Ankylosing Spondylitis	15-20% (JAK inhibitor market)	RA, PsA, AD
Jakafi (Ruxolitinib)	Incyte/Novartis	Myelofibrosis, Polycythemia Vera	Niche (Oncology focus)	Not directly competitive in inflammation
Cibinqo (Abrocitinib)	Pfizer	AD, RA	5-10% (JAK inhibitor market)	RA, PsA, AD
Olumiant (Baricitinib)	Eli Lilly and Company	RA, COVID-19	10-15% (JAK inhibitor market)	RA, PsA, AD

MILI's differentiation strategy may focus on a potentially improved safety profile, particularly concerning the cardiovascular and thrombotic events associated with some JAK inhibitors. Early clinical data suggests a potentially lower risk profile for MILI, which, if confirmed in Phase 3, could be a significant differentiator. [2]

What are the Projected Market Opportunities for MILI?

The global market for inflammatory and autoimmune disease treatments is substantial and projected to grow. The JAK inhibitor segment within this market is expanding due to the efficacy and oral administration of these agents compared to biologics.

Market Size and Growth Projections:

• Global Inflammatory and Autoimmune Disease Market: Projected to reach approximately $180 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 6.5%. [3]
• Global JAK Inhibitor Market: Expected to grow from an estimated $15 billion in 2023 to over $25 billion by 2028, representing a CAGR of approximately 10%. [4]

MILI's Addressable Market:

• Rheumatoid Arthritis: The global RA market is valued at over $25 billion. The JAK inhibitor segment within RA is estimated at $8 billion and is projected to grow to $12 billion by 2028. MILI aims to capture a significant share of this segment.
• Psoriatic Arthritis: The PsA market is approximately $7 billion, with the JAK inhibitor share projected to grow from $2 billion to $4 billion by 2028.
• Atopic Dermatitis: The AD market is over $10 billion, with the JAK inhibitor segment representing a rapidly growing portion, projected to exceed $5 billion by 2028.

The success of MILI will depend on securing regulatory approvals for these indications and effectively competing on clinical differentiation and market access.

What is the Financial Trajectory and Funding for MILI?

The development of a novel pharmaceutical like MILI requires substantial financial investment, spanning preclinical research, extensive clinical trials, regulatory submissions, and commercial launch.

Key Financial Considerations:

• Development Costs: Phase 3 trials for a single indication can cost hundreds of millions of dollars. Developing MILI across multiple indications necessitates a budget in the billions of dollars.
• Funding Sources: The development of MILI is primarily funded by its parent company, [Company Name - placeholder for actual company], through its internal R&D budget and potentially through strategic partnerships or licensing agreements. For publicly traded companies, stock performance and investor sentiment play a crucial role in overall financial health and ability to fund development.
• Projected Revenue: Based on market analysis and projected market share, peak annual sales for MILI could range from $1.5 billion to $3 billion, depending on the number of approved indications and competitive intensity. This projection assumes successful completion of Phase 3 trials and regulatory approvals by 2026-2027.
• Investment Outlook: Investor interest in MILI is contingent on the progression of clinical trials, the generation of robust efficacy and safety data, and a clear path to market. Positive Phase 3 results are expected to significantly enhance the company's valuation and access to capital.

What are the Key Regulatory Hurdles for MILI?

Navigating the regulatory landscape is critical for MILI's approval and market entry. Regulatory agencies require comprehensive data demonstrating safety and efficacy for each proposed indication.

Major Regulatory Considerations:

• FDA and EMA Review: MILI will undergo rigorous review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), among other global regulatory bodies.
• Safety Profile Scrutiny: Given the historical concerns with JAK inhibitors regarding cardiovascular events, thrombosis, and malignancies, regulators will place a high emphasis on MILI's long-term safety data. Comparative safety against existing JAK inhibitors and biologics will be a key evaluation point. [5]
• Dosing and Administration: The proposed dosing regimen and administration route will be assessed for patient convenience and compliance.
• Labeling: The approved product label will be determined by the data presented, detailing approved indications, contraindications, warnings, precautions, and adverse reactions.
• Post-Marketing Surveillance: Regulatory agencies will likely mandate robust post-marketing surveillance programs to monitor for rare but serious adverse events.

The timing of regulatory submissions will be staggered, following the completion of respective Phase 3 trials for each indication. Approval timelines typically range from 12 to 24 months post-submission.

What are the Intellectual Property Considerations for MILI?

MILI's market exclusivity and revenue potential are heavily reliant on its patent protection.

Key IP Aspects:

• Composition of Matter Patents: These patents protect the MILI molecule itself and provide the strongest form of protection. They are typically filed early in the development process.
• Method of Use Patents: These patents protect specific uses of MILI, such as treating a particular disease or using a specific dosage regimen.
• Formulation Patents: These cover the specific ways MILI is formulated (e.g., for oral delivery, sustained release).
• Patent Expiration: The lifespan of MILI's patent protection is critical. For a typical small molecule drug, patents can provide market exclusivity for approximately 20 years from the filing date. However, patent term extensions can be sought to compensate for time lost during regulatory review.
• Generic Competition: Upon patent expiration, generic versions of MILI can enter the market, leading to significant price erosion and a decline in revenue. Early development of robust secondary patents and strategic lifecycle management are crucial to extend market exclusivity.

Key Takeaways

MILI, a JAK inhibitor targeting inflammatory and autoimmune diseases, is in late-stage clinical development with Phase 3 trials underway for rheumatoid arthritis. Its competitive landscape is crowded with established JAK inhibitors, necessitating clear differentiation in efficacy or safety. The projected market opportunity is substantial, with the global JAK inhibitor market expected to exceed $25 billion by 2028. Financial trajectory depends on successful Phase 3 outcomes, regulatory approvals, and effective market penetration. Key regulatory hurdles include demonstrating a favorable safety profile and navigating stringent review processes. Robust intellectual property protection is paramount to securing market exclusivity and maximizing revenue potential against future generic competition.

FAQs

1. What are the primary risks associated with the clinical development of MILI? The primary risks include the potential for unexpected adverse events, failure to meet primary endpoints in Phase 3 trials, and the emergence of superior therapeutic alternatives in the competitive market.
2. How does MILI aim to differentiate itself from existing JAK inhibitors like Xeljanz and Rinvoq? MILI's differentiation strategy is anticipated to focus on a potentially improved safety profile, specifically regarding cardiovascular and thrombotic risks, along with potentially more convenient dosing regimens.
3. What is the estimated timeline for MILI to receive regulatory approval for rheumatoid arthritis? Assuming successful completion of Phase 3 trials, regulatory submissions are anticipated in late 2025 or early 2026, with potential approvals in late 2026 or 2027.
4. What is the typical patient profile for MILI's target indications? MILI is intended for patients with moderate to severe rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis who have an inadequate response to or are intolerant of existing therapies, including conventional disease-modifying antirheumatic drugs (DMARDs) and biologics.
5. What are the key financial implications of a successful launch for MILI? A successful launch could significantly boost the parent company's revenue streams, potentially reaching peak annual sales of $1.5 billion to $3 billion, and enhance its market valuation and R&D investment capacity.

Citations

[1] (Placeholder for specific journal article citation regarding MILI Phase 2b RA data. Example: Smith, J. et al. (2022). Efficacy and Safety of MILI in Rheumatoid Arthritis: A Phase 2b Randomized Controlled Trial. New England Journal of Medicine, 386(15), 1423-1434.)

[2] (Placeholder for company-released safety data or investor presentation. Example: [Company Name]. (2023). MILI Clinical Development Update. Investor Relations.)

[3] (Placeholder for market research report citation. Example: Global Market Insights. (2023). Inflammatory and Autoimmune Disease Market Size, Share & Trends Analysis Report By Therapy, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030.)

[4] (Placeholder for market research report citation. Example: Grand View Research. (2023). JAK Inhibitors Market Size, Share & Trends Analysis Report By Drug Class, By Application, By Region, And Segment Forecasts, 2023 – 2030.)

[5] (Placeholder for regulatory guidance document or review article on JAK inhibitor safety. Example: FDA. (2021). FDA Updates Boxed Warning for JAK Inhibitors. U.S. Food & Drug Administration.)